Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation
- PMID: 15546907
- DOI: 10.1210/jc.2004-0509
Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation
Abstract
Although osteoporosis is a relatively common complication after allogeneic stem cell transplantation, the role of bisphosphonates in its management has not yet been completely established. Thirty-two patients who underwent allogeneic stem cell transplantation were prospectively evaluated for bone mineral density (BMD) at the lumbar spine (LS) and femoral neck (FN) after a median period of 12.2 months. Then, 15 of the patients with osteoporosis or rapidly progressing osteopenia (bone loss > 5%/yr) received three monthly doses of 4 mg zoledronic acid iv. Fifteen patients were followed up without treatment, and all 30 patients were reevaluated after 12 months for BMD and bone turnover markers. By using enriched mesenchymal stem cells in the colony-forming units fibroblast (CFU-F) assay, we evaluated the osteogenic stromal lineage. This procedure was performed in both groups of patients at study entry and after 12 months. The average BMD loss was 3.42% at LS and 3.8% at FN during a 1-yr longitudinal evaluation in 32 patients. Subsequently, BMD increased at both LS and FN (9.8 and 6.4%, respectively) in the zoledronic acid-treated cohort. Hydroxyproline excretion decreased, and serum bone-specific alkaline phosphatase increased significantly, whereas serum osteocalcin increase did not reach the limit of significance. A significant increase in CFU-F growth in vitro was induced by in vivo zoledronic acid administration. In the untreated group, no significant change was observed in bone turnover markers, LS BMD (-2.1%), FN BMD (-2.3%), and CFU-F colony number. In conclusion, short-term zoledronic acid treatment consistently improved both LS and FN BMD in transplanted patients who were at high risk for fast and/or persistent bone loss, partly by increasing the osteogenic progenitors in the stromal cell compartment.
Similar articles
-
Long-lasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation.J Clin Endocrinol Metab. 2002 Nov;87(11):5058-65. doi: 10.1210/jc.2002-020800. J Clin Endocrinol Metab. 2002. PMID: 12414872
-
Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.Metabolism. 2015 Oct;64(10):1291-7. doi: 10.1016/j.metabol.2015.06.018. Epub 2015 Jun 27. Metabolism. 2015. PMID: 26198440 Clinical Trial.
-
Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation.Biol Blood Marrow Transplant. 2013 Sep;19(9):1361-7. doi: 10.1016/j.bbmt.2013.06.015. Epub 2013 Jun 24. Biol Blood Marrow Transplant. 2013. PMID: 23806773 Clinical Trial.
-
Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: a meta-analysis.Asian Pac J Trop Med. 2012 Sep;5(9):743-8. doi: 10.1016/S1995-7645(12)60118-7. Asian Pac J Trop Med. 2012. PMID: 22805729 Review.
-
Bone loss and its management in long-term survivors from allogeneic stem cell transplantation.J Clin Endocrinol Metab. 2007 Dec;92(12):4536-45. doi: 10.1210/jc.2006-2870. Epub 2007 Oct 2. J Clin Endocrinol Metab. 2007. PMID: 17911175 Review.
Cited by
-
Bone loss after allogeneic haematopoietic stem cell transplantation: a pilot study on the use of zoledronic Acid.Chemother Res Pract. 2012;2012:858590. doi: 10.1155/2012/858590. Epub 2012 Apr 10. Chemother Res Pract. 2012. PMID: 22550587 Free PMC article.
-
Osteoporosis management in hematologic stem cell transplant recipients: Executive summary.J Bone Oncol. 2021 Apr 23;28:100361. doi: 10.1016/j.jbo.2021.100361. eCollection 2021 Jun. J Bone Oncol. 2021. PMID: 33996429 Free PMC article. Review.
-
Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease.Biol Blood Marrow Transplant. 2018 Jul;24(7):1415-1423. doi: 10.1016/j.bbmt.2018.02.019. Epub 2018 Mar 1. Biol Blood Marrow Transplant. 2018. PMID: 29496562 Free PMC article.
-
Osteoclast activity modulates B-cell development in the bone marrow.Cell Res. 2011 Jul;21(7):1102-15. doi: 10.1038/cr.2011.21. Epub 2011 Feb 15. Cell Res. 2011. PMID: 21321604 Free PMC article.
-
A Novel Germline Mutation of ADA2 Gene in Two "Discordant" Homozygous Female Twins Affected by Adenosine Deaminase 2 Deficiency: Description of the Bone-Related Phenotype.Int J Mol Sci. 2021 Aug 3;22(15):8331. doi: 10.3390/ijms22158331. Int J Mol Sci. 2021. PMID: 34361096 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous